This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McKee, T. D. Articles by Jain, R. K. Search for Related Content PubMed PubMed Citation Articles by McKee, T. D. Articles by Jain, R. K.

Degradation of Fibrillar Collagen in a Human Melanoma Xenograft Improves the Efficacy of an Oncolytic Herpes Simplex Virus Vector

¹ Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachussetts; ² Biological Engineering Division, ³ Departments of Chemical Engineering and ⁴ Chemistry, Massachusetts Institute of Technology, Cambridge, Massachussetts; and ⁵ Departments of Neurology and Radiology, Massachusetts General Hospital, and Neuroscience Program, Harvard Medical School, Charlestown, Massachussetts

Requests for reprints: Rakesh K. Jain, Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom Street, Cox 7, Boston, MA 02114. Phone: 617-726-4083; Fax: 617-724-1819; E-mail: jain{at}steele.mgh.harvard.edu.

Oncolytic viral therapy provides a promising approach to treat certain human malignancies. These vectors improve on replication-deficient vectors by increasing the viral load within tumors through preferential viral replication within tumor cells. However, the inability to efficiently propagate throughout the entire tumor and infect cells distant from the injection site has limited the capacity of oncolytic viruses to achieve consistent therapeutic responses. Here we show that the spread of the oncolytic herpes simplex virus (HSV) vector MGH2 within the human melanoma Mu89 is limited by the fibrillar collagen in the extracellular matrix. This limitation seems to be size specific as nanoparticles of equivalent size to the virus distribute within tumors to the same extent whereas smaller particles distribute more widely. Due to limited viral penetration, tumor cells in inaccessible regions continue to grow, remaining out of the range of viral infection, and tumor eradication cannot be achieved. Matrix modification with bacterial collagenase coinjection results in a significant improvement in the initial range of viral distribution within the tumor. This results in an extended range of infected tumor cells and improved virus propagation, ultimately leading to enhanced therapeutic outcome. Thus, fibrillar collagen can be a formidable barrier to viral distribution and matrix-modifying treatments can significantly enhance the therapeutic response. (Cancer Res 2006; 66(5): 2509–13)

This article has been cited by other articles:

				F. Sabeh, R. Shimizu-Hirota, and S. J. Weiss Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited J. Cell Biol., April 6, 2009; 185(1): 11 - 19. [Abstract] [Full Text] [PDF]

				W. Mok, T. Stylianopoulos, Y. Boucher, and R. K. Jain Mathematical Modeling of Herpes Simplex Virus Distribution in Solid Tumors: Implications for Cancer Gene Therapy Clin. Cancer Res., April 1, 2009; 15(7): 2352 - 2360. [Abstract] [Full Text] [PDF]

				E. Blanco, C. W. Kessinger, B. D. Sumer, and J. Gao Multifunctional Micellar Nanomedicine for Cancer Therapy Experimental Biology and Medicine, February 1, 2009; 234(2): 123 - 131. [Abstract] [Full Text] [PDF]

				S. Libertini, I. Iacuzzo, G. Perruolo, S. Scala, C. Ierano, R. Franco, G. Hallden, and G. Portella Bevacizumab Increases Viral Distribution in Human Anaplastic Thyroid Carcinoma Xenografts and Enhances the Effects of E1A-Defective Adenovirus dl922-947 Clin. Cancer Res., October 15, 2008; 14(20): 6505 - 6514. [Abstract] [Full Text] [PDF]

				J. Henshaw, B. Mossop, and F. Yuan Relaxin treatment of solid tumors: effects on electric field-mediated gene delivery Mol. Cancer Ther., August 1, 2008; 7(8): 2566 - 2573. [Abstract] [Full Text] [PDF]

				M. E. Ackerman, D. Pawlowski, and K. D. Wittrup Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids Mol. Cancer Ther., July 1, 2008; 7(7): 2233 - 2240. [Abstract] [Full Text] [PDF]

				S. Nagano, J. Y. Perentes, R. K. Jain, and Y. Boucher Cancer Cell Death Enhances the Penetration and Efficacy of Oncolytic Herpes Simplex Virus in Tumors Cancer Res., May 15, 2008; 68(10): 3795 - 3802. [Abstract] [Full Text] [PDF]

				Y. Y. Mahller, S. S. Vaikunth, M. C. Ripberger, W. H. Baird, Y. Saeki, J. A. Cancelas, T. M. Crombleholme, and T. P. Cripe Tissue Inhibitor of Metalloproteinase-3 via Oncolytic Herpesvirus Inhibits Tumor Growth and Vascular Progenitors Cancer Res., February 15, 2008; 68(4): 1170 - 1179. [Abstract] [Full Text] [PDF]

				A. Khaibullina, B.-S. Jang, H. Sun, N. Le, S. Yu, V. Frenkel, J. A. Carrasquillo, I. Pastan, K. C.P. Li, and C. H. Paik Pulsed High-Intensity Focused Ultrasound Enhances Uptake of Radiolabeled Monoclonal Antibody to Human Epidermoid Tumor in Nude Mice J. Nucl. Med., February 1, 2008; 49(2): 295 - 302. [Abstract] [Full Text] [PDF]

				D. Kolodkin-Gal, G. Zamir, Y. Edden, E. Pikarsky, A. Pikarsky, H. Haim, Y. S. Haviv, and A. Panet Herpes Simplex Virus Type 1 Preferentially Targets Human Colon Carcinoma: Role of Extracellular Matrix J. Virol., January 15, 2008; 82(2): 999 - 1010. [Abstract] [Full Text] [PDF]

				M. Magzoub, S. Jin, and A. S. Verkman Enhanced macromolecule diffusion deep in tumors after enzymatic digestion of extracellular matrix collagen and its associated proteoglycan decorin FASEB J, January 1, 2008; 22(1): 276 - 284. [Abstract] [Full Text] [PDF]

				W. Mok, Y. Boucher, and R. K. Jain Matrix Metalloproteinases-1 and -8 Improve the Distribution and Efficacy of an Oncolytic Virus Cancer Res., November 15, 2007; 67(22): 10664 - 10668. [Abstract] [Full Text] [PDF]

				H. Li, Z. Zeng, X. Fu, and X. Zhang Coadministration of a Herpes Simplex Virus-2 Based Oncolytic Virus and Cyclophosphamide Produces a Synergistic Antitumor Effect and Enhances Tumor-Specific Immune Responses Cancer Res., August 15, 2007; 67(16): 7850 - 7855. [Abstract] [Full Text] [PDF]

				S. V. Kozin, F. Winkler, I. Garkavtsev, D. J. Hicklin, R. K. Jain, and Y. Boucher Human Tumor Xenografts Recurring after Radiotherapy Are More Sensitive to Anti-Vascular Endothelial Growth Factor Receptor-2 Treatment than Treatment-Naive Tumors Cancer Res., June 1, 2007; 67(11): 5076 - 5082. [Abstract] [Full Text] [PDF]

				S. Ganesh, M. Gonzalez Edick, N. Idamakanti, M. Abramova, M. VanRoey, M. Robinson, C.-O. Yun, and K. Jooss Relaxin-Expressing, Fiber Chimeric Oncolytic Adenovirus Prolongs Survival of Tumor-Bearing Mice Cancer Res., May 1, 2007; 67(9): 4399 - 4407. [Abstract] [Full Text] [PDF]